Form 4: United Therapeutics COO Exercises Options and Sells Shares Under 10b5-1 Plan

Sentiment:

SEC Form 4 Filing


United Therapeutics' President and COO, Michael Benkowitz, executed stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

  • Michael Benkowitz, President and COO of United Therapeutics, exercised stock options and sold shares of the company's common stock on November 18, 2024.
  • These transactions were executed under a pre-arranged Rule 10b5-1 trading plan established on August 7, 2024.
  • The transactions involved the exercise of 10,000 stock options at prices of $102.11 and $111, and the subsequent sale of 7,500 shares at prices ranging from $356.415 to $362.0202.
  • The shares were sold in multiple trades at varying prices, with weighted average prices reported for each set of transactions.
  • The transactions were conducted through a trust where Mr. Benkowitz is a co-trustee and beneficiary, and another trust where his family members are beneficiaries.

Sentiment

Score: 5

Explanation: The document reflects routine transactions under a pre-existing plan, with no indication of positive or negative sentiment.

Industry Context

This is a routine filing related to executive compensation and pre-planned stock sales, which is common in publicly traded companies.

Comparison to Industry Standards

  • The use of 10b5-1 trading plans is a standard practice for corporate executives to avoid accusations of insider trading.
  • The reported prices are within the typical range for stock transactions of this nature.
  • The volume of shares sold is not unusual for an executive exercising stock options.

Stakeholder Impact

  • The transactions have a minor impact on shareholders as they represent a small portion of the total outstanding shares.
  • The transactions are part of the executive compensation plan and do not indicate any change in the company's operations or outlook.

Key Dates

DateDescription
06/24/2017Date the first set of stock options became exercisable.
03/15/2019Date the second set of stock options became exercisable.
08/07/2024Date the Rule 10b5-1 trading plan was established.
11/18/2024Date of the stock option exercise and share sales.
11/19/2024Date the Form 4 was signed.
06/24/2026Expiration date of the first set of stock options.
03/15/2028Expiration date of the second set of stock options.

Keywords

stock options, Rule 10b5-1, insider trading, share sale, United Therapeutics, UTHR, Michael Benkowitz, executive compensation

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.